Showing 2141-2150 of 2526 results for "".
- Study to Investigate If Those With Diabetic Eye Disease Are At Greater Risk of COVID-19 Complicationshttps://modernod.com/news/study-to-investigate-if-those-with-diabetic-eye-disease-are-at-greater-risk-of-covid-19-complications/2478267/Fight for Sight is partnering with Diabetes UK to investigate if people with diabetic retinopathy are at greater risk of developing complications from COVID-19, in a study that hopes to save lives. This research, which will be carried out at the University of Edinburgh, will investigate wh
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d
- Seva Foundation Partners With IrisVision to Democratize Vision Care Through Innovationhttps://modernod.com/news/seva-foundation-partners-with-irisvision-to-democratize-vision-care-through-innovation/2478208/IrisVision announced it has partnered with the Seva Foundation to develop new technology that aims to democratize vision healthcare around the world. In the first phase of this unique public-private partnership, Seva, a global non-profit organization that provides eye
- Clearside Biomedical Expands Patent Portfolio in the US and Europehttps://modernod.com/news/clearside-biomedical-expands-patent-portfolio-in-the-us-and-europe/2478203/Clearside Biomedical announced the recent issuance of three additional patents in the United States and Europe. The United States Patent and Trademark Office (USPTO) recently granted patent number 10,722,396 to Clearside. This patent covers Clearside’s SCS M
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- Hospital Operating Margins Down 28% Through July: Reporthttps://modernod.com/news/hospital-operating-margins-down-28-through-july-report/2478199/While there have been some early signs of recovery, uncertainty and volatility caused by the COVID-19 pandemic continued to rock hospital financials through the end of July, a new report says, according to a FierceHealthcare
- American Academy of Optometry Foundation Announces the 2020 Alfred A. Rosenbloom Jr. Low Vision Residency Award Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-alfred-a-rosenbloom-jr-low-vision-residency-award-recipient/2478194/The American Academy of Optometry has announced that Carolyn N. Chakuroff, OD, MS, is this year’s recipient of the Alfred A. Rosenbloom Jr. Low Vision Residency Award. Dr. Chakuroff is a graduate of The Ohio State University College of Optometry and an Ocular Disease/Low Vision Rehabilitation res
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trialhttps://modernod.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/A phase 3 trial Johnson & Johnson is planning to get under way in September to test its coronavirus vaccine candidate Ad26.COV2.S is looking to recruit up to 60,000 participants globally, the company confirmed Thursday. The targeted enrollment, first reported on the ClinicalTrials.gov databas